Category: HIDE FROM HOME

Best Mart 360 Announces 2025 Annual Results

Recorded Continuous Growth in Revenue, Proposed a final dividend of HK9.0 cents per share

Highlights:

Revenue increased by 2.2% to approximately HK$2,867.7 million.
Gross profit increased by 0.7% to approximately HK$1,035.1 million.
Profit attributable to owners of the Company recorded approximately HK$219.7 million.
As at 31 December 2025, the Group operated a total of 183 chain retail stores (2024: 176), including 178 retail stores in Hong Kong and 5 retail stores in Macau.
Basic earnings per share was approximately HK22.0 cents. The Board recommended the payment of final dividend of HK9.0 cents per share.

Financial Highlights:

HK$’000	Year ended 31 Dec 2025	Year ended 31 Dec 2024 (Restated)	Change
Revenue	2,867,695	2,805,146	+2.2%
Gross profit	1,035,074	1,027,997	+0.7%
Gross profit margin	36.1%	36.6%	-0.5 p.p.
Profit attributable to owners of the Company	219,730	245,901	-10.6%

HONG KONG SAR – Media OutReach Newswire – 27 March 2026 – Best Mart 360 Holdings Limited (“Best Mart 360” or the “Company”, together with its subsidiaries, the “Group”; stock code: 2360.HK), a leisure food retailer in Hong Kong, announced its results for the year ended 31 December 2025. During the year, the revenue recorded by the Group amounted to approximately HK$2,867,695,000 (2024: HK$2,805,146,000), representing an increase of approximately 2.2%.

During the Financial Year under Review, gross profit was approximately HK$1,035,074,000 (2024: HK$1,027,997,000), representing an increase of 0.7%. The Group’s gross profit margin for the year was approximately 36.1%, compared to approximately 36.6% in 2024. This contraction in margin was primarily attributable to the strategic implementation of enhanced promotional campaigns designed to navigate the ongoing trend of consumption downgrading and intensified market competition.

Profit attributable to owners of the Company for the year was approximately HK$219,730,000 (2024 (Restated): approximately HK$245,901,000), primarily due to a slight reduction in average revenue per store and a contraction in gross profit margin, which collectively impacted overall profitability. The net profit margin (before interest and tax) moderated to approximately 9.8%, down from approximately 11.2% for the year ended 31 December 2024 (Restated).

For the Financial Year under Review, basic earnings per share was approximately HK22.0 cents. The Board recommended the payment of final dividend of HK9.0 cents per share.

BUSINESS REVIEW
Strategy Adjustment & Opened 10New Retail Stores
As at 31 December 2025, the Group operated a total of 183 chain retail stores, including 178 chain retail stores (31 December 2024: 170 stores) in Hong Kong and 5 chain retail stores (31 December 2024: 6 stores) in Macau respectively. During the Financial Year under Review, the Group opened 10 new retail stores and closed 3 stores upon expiration of their respective lease terms in alignment with the Group’s strategy adjustment.

The ratio of rental expense (cash basis) to sales revenue of retail stores for the year ended 31 December 2025 was approximately 9.6%, which was similar to that of approximately 9.6% for the year ended 31 December 2024.

Introduced Popular Brands & Launched on Grocery Delivery Platform
Hong Kong residents’ growing propensity to spend in Mainland China, coupled with inbound visitors’ preference for in-depth experiences, more rational and prudent consumption patterns, as well as the intensified competition in the local market from Mainland China e-commerce players leveraging economies of scale, the Hong Kong retail market is undergoing a structural long-term transformation, with the industry’s competitive landscape and consumption behaviour being reshaped.

In response to the challenging business environment, the Group adopted a series of timely and targeted measures to navigate these difficulties. These included optimizing product mix and strengthening the offering of basic foodstuffs covering cereals, noodles, canned food, milk, chilled and frozen food, daily necessities as well as basic groceries. The Group also introduced popular Mainland brands as well as imported a wide range of specialty food from around the world to meet the needs and expectations of local consumers and visiting tourists. To further strengthen its business, the Group launched on the Foodpanda grocery delivery platform during 2025 to expand its online sales channels, and rolled out a variety of promotional initiatives including shopping vouchers. These initiatives collectively contributed to the Group’s sales growth during the Financial Year under Review.

The Group procured quality products from overseas suppliers as well as brand owners or importers in Hong Kong. For the year ended 31 December 2025, the Group offered a total of approximately 3,425 stock keeping units (“SKU”) of products (for the year ended 31 December 2024: approximately 3,653 SKU) from suppliers principally from (but not limited to) Japan, Mainland China, Europe, Vietnam, Korea, the United States and other Asia-Pacific countries.

The Group sourced the most popular and trendy food products from various regions, striving to provide customers with diverse, multi-brand, and multi-category global product choices.

As at 31 December 2025, the total amount of inventories of the Group amounted to approximately HK$316,841,000 (31 December 2024: approximately HK$339,513,000), representing a decrease of approximately 6.7% year-on-year. The decrease in the Group’s total inventories was mainly attributable to optimised inventory management and the timing shift of the Lunar New Year holiday from January to February.

During the Financial Year under Review, the Group continued to actively develop private label products that on one hand allowed the Group to capture pricing advantages and exercise a higher level of quality control over its products and on the other hand further uplift its brand awareness and strengthen customers’ loyalty. For the Financial Year under Review, sales derived from private label products were approximately HK$520,821,000 (for the year ended 31 December 2024: approximately HK$477,222,000), accounted for approximately 18.2% of the Group’s revenue for the Financial Year under Review (for the year ended 31 December 2024: approximately 17.0%).

Expanded Customer Base & Enhanced Loyalty
To further deepen customer stickiness and broaden customers coverage, the Group used big data analysis and reformulated its marketing strategy to launch a new three-tier membership scheme and a second-generation mobile app in mid-June 2020. The new membership scheme helps to elevate brand positioning and market recognition, and the membership rewards have been fully optimised and enhanced, with more member benefits such as stamp reward for multiple-item purchase, special offers for selected products and access to the latest market information. During the Financial Year under Review, the number of the Group’s members increased from approximately 2,280,418 as at 31 December 2024 to approximately 2,395,862 as at 31 December 2025, representing an increase of approximately 5.1%.

The Group launched various marketing and promotional activities during the Financial Year under Review including the “Best Price” promotional campaign, which provided customers with a series of special offers for selected quality products from time to time to enhance customer loyalty. Meanwhile, the Group continued to advertise through television, newspapers, social media platforms and other media, which successfully attracted new customers encouraged repeat purchases and significantly enhanced market awareness of the Group.

PROSPECTS
Looking ahead, uncertainties in Sino-US relations, geopolitical risks and other factors will introduce further variables to economic recovery, and economic growth in Hong Kong and globally is expected to remain under pressure. The Board anticipates that the retail sector in Hong Kong will remain challenging in the near term. Nevertheless, the Group will continue to operate in a cautiously optimistic manner, closely monitor the development of various adverse factors that may impact the Group’s performance, and timely implement necessary and appropriate measures through refined operations and management to adapt to the ever-changing market environment.

The Group will continue to prioritize the Hong Kong market as its core focus, optimize its product mix and enhance the development of its private label products, with a wider range of staple foods and necessities to better meet consumer demand and enhance the Group’s competitiveness in the retail market.

To maintain sound operational efficiency, the Group will timely review the regional distribution of its brand stores, implement a moderate expansion policy and flexible leasing strategies, and actively pursue suitable opportunities to expand the retail network for its core retail brand “Best Mart 360º” and global gourmet brand “FoodVille” in Hong Kong and Macau, targeting a net increase of 10 retail stores annually under its dual-brand model, catering to the diverse needs of different customer segments for quality food products.

Mr. Hui Chi Kwan, Chief Executive Officer of the Group, said, “Faced with an increasingly complex operating environment, the Group will maintain a prudent and pragmatic approach in its operations and continue to work closely with its employees, customers and other stakeholders, striving to improve business performance and deliver stable returns to shareholders.”

Hashtag: #BestMart360 #優品360 #AnnualResults #業績 #全年業績

The issuer is solely responsible for the content of this announcement.

Best Mart 360 Holdings Limited

Best Mart 360 Holdings Limited operates chain retail stores under the brand “Best Mart 360˚”, offering wide selection of imported and pre-packaged leisure foods and other grocery products principally from overseas. It is the Group’s business objective to offer “Best Quality” and “Best Price” products to customers through continuous efforts on global procurement with a mission to provide comfortable shopping environment and pleasurable shopping experience to customers. As at 31 December 2025, the Group operated a total of 183 chain retail stores, spanning all of the 18 districts in Hong Kong and strategic locations with heavy pedestrian flow in Macau. Among the chain retail stores, the global gourmet brand “FoodVille” launched in September 2021 is also included, targeting the medium-to-high-end-market.

March 27, 2026

優品360發佈2025全年業績

收入持續錄增長擬派股息每股9.0港仙　

摘要：

收入錄得約2,867.7百萬港元，按年增加約2.2%
毛利錄得約1,035.1百萬港元，按年增加約0.7%
公司擁有人應佔溢利錄得約219.7百萬港元
於2025年12月31日，集團零售店舖數目為183間（2024年：176間），包括香港178間及澳門5間
每股盈利約22.0港仙；董事會建議派發股息每股9.0港仙

財務摘要：

千港元	截至2025年 12月31日止年度	截至2024年 12月31日止年度 (經重列)

香港 – Media 變幅收入 2,867,695 2,805,146 +2.2% 毛利 1,035,074 1,027,997 +0.7% 毛利率 36.1% 36.6% -0.5百分點 公司擁有人應佔溢利 219,730 245,901 -10.6% OutReach Newswire – 2026年3月27日 – 本港休閒食品零售商優品360控股有限公司（「優品360」或「本公司」及其子公司：「集團」；股票編號：2360.HK）宣佈其截至2025年12月31日止之全年業績。於2025年度，集團錄得收入約2,867,695,000港元（2024年：2,805,146,000港元），同比增加約2.2%，主要由於本集團在年度淨增設的7間新店舖，帶來額外營業額。

於回顧財政年度，毛利約為1,035,074,000港元（2024年：1,027,997,000 港元），增加約0.7%；回顧財政年度的毛利率約為36.1%（2024年：36.6%），毛利率收窄主要由於本集團為應對持續的消費降級趨勢及加劇的市場競爭，策略性地加強了促銷活動。

於2025年度，本公司擁有人應佔溢利約為219,730,000港元（2024年（經重列）：約245,901,000港元），主要由於店均收入輕微下降及毛利率收窄，共同影響了整體盈利能力。除息稅前純利率自2024年度（經重列）的約11.2% 溫和下降至約9.8%。

於財政年度，每股盈利約為22.0港仙，董事會建議派付末期股息每股9.0 港仙。

業務概況

策略性調整分店策略 新增10間零售店舖

於2025年12月31日，集團合共經營183間連鎖零售店舖（於2024年12月31日：176間），當中在香港地區經營178間店舖（於2024年12月31日：170間店舖），以及澳門地區5間店舖（於2024年12月31日：6間店舖）。年內，集團新開設了10間零售店舖，並因集團的策略調整，在相關店舖租期屆滿時關閉了3間店舖。

截至2025年12月31日止年度零售店舖的租金開支（現金基準）對銷售收入比率約為9.6%，接近截至2024年12月31日止年度的約9.6%。

積極引入品牌 上線雜貨配送平台

隨著港人北上消費意欲持續提升，加上訪港旅客偏向深度體驗，整體市場消費取態趨向理性及審慎，同時內地電商憑藉規模效應積極競逐本地市場，本港零售市場正經歷結構性的長期轉變。

面對充滿挑戰的營商環境，本集團因時制宜推行多項措施帶領業務走出困局，包括優化產品結構，除了鞏固增強穀類、麵食、罐頭食品、牛奶、冰鮮及急凍食物等基本食品、生活必需品和基本雜貨產品，本集團亦積極引入內地熱門品牌，同時進口各類環球特色食品，以滿足本地社區消費者及旅客的需求和期望。為進一步強化業務發展，本集團於2025年上線Foodpanda雜貨配送平台，拓寬線上銷售渠道，並推出購物現金券等多元化推廣活動。各項舉措共同帶動本集團於回顧財政年度仍錄得銷售增長。

本集團自海外供應商、香港品牌商及進口商採購優質產品。截至2025年12月31日止年度，本集團銷售產品約3,425 個SKU（截至2024年12月31日止年度：約3,653 個SKU），供應商主要來源地包括（但不限於）日本、中國內地、歐洲、越南、韓國、美國及其他亞太地區國家。本集團於各地區採購當下最受歡迎及具時尚性的食品，致力為客戶提供環球多元、多品牌、多類別的產品選擇。

於2025年12月31日，集團總存貨量約值316,841,000港元（2024年12月31日：約339,513,000 港元），按年下跌約6.7%，主要由於存貨管理優化，及2025年農曆新年假期由1月變為2月。

於回顧財政年度，集團繼續積極開發自家品牌產品，除有助集團捕捉價格優勢，以及對產品可行使較高程度的品質監控外，亦可進一步提升集團的品牌知名度及加深顧客忠誠度。於回顧財政年度，自家品牌產品的銷售額約520,821,000 港元（截至2024年12月31日止年度：約477,222,000港元），佔本集團回顧財政年度的收入約18.2%（截至2024年12月31日止年度：約17.0%）。

擴展顧客基礎提升忠誠度

為進一步深化顧客的黏性及擴大其覆蓋面，本集團運用大數據分析及重新制定營銷策略，持續推行三級制會員計劃及手機應用程式。會員計劃有助提升品牌定位及市場知名度，而會員獎賞亦全面優化及提升，享有更多會員福利如印花複購、精選產品優惠及接收最新市場資訊等。於回顧財政年度，集團會員數目由2024年12月31日約2,280,418 名，增加至2025年12月31日約2,395,862 名，增幅約5.1%。

集團於年內繼續推出不同市場推廣活動，包括「至優價」優惠活動，不時為顧客提供一系列精選優質產品價格優惠，以提升顧客忠誠度。本集團繼續透過電視、報紙、社交平台等媒介進行廣告宣傳，在成功增加顧客回頭率的同時，吸引新顧客光臨，大大增加本集團於市場上之討論熱度。

未來展望

中美關係的不確定性、地緣政治風險等將為經濟復甦增添變數，本港以至全球經濟增長可能將持續受壓。預期本港零售業短期內仍然充滿挑戰，本集團將繼續以審慎樂觀的態度經營業務，密切留意影響本集團營運的各項不利因素發展，透過精細化經營管理，及時實施必要且適當的業務措施，以應對瞬息萬變的市場環境。

本集團將繼續以香港市場為發展重心，透過優化產品組合和加強自家品牌的研發，涵蓋更多基本食品及必需品，以更好滿足消費者的需求，提升本集團於零售市場中的競爭力。

為維持穩健的營運效益，本集團將適時審視旗下品牌店舖的區域分布，並採取適度的擴張政策及靈活的租賃策略，把握合適機會拓展旗下核心零售品牌「優品360º」及環球美酒食品品牌「FoodVille」於香港及澳門的店舖網絡，目標每年淨增加10 間零售店舖，以雙品牌模式迎合不同顧客群對優質食品的需求。

集團行政總裁許志群先生表示：「面對日益複雜的經營環境，本集團將秉持審慎務實的態度，繼續與員工、顧客及其他持份者緊密合作，致力提升業務表現，為股東創造穩健回報。」

Hashtag: #BestMart360 #優品360 #AnnualResults #業績 #全年業績

The issuer is solely responsible for the content of this announcement.

關於優品360控股有限公司

優品360控股有限公司主要以品牌「優品360˚」經營連鎖零售店舖，向顧客提供多種主要來自海外的進口預先包裝休閒食品及其他雜貨產品。集團的宗旨是通過不斷努力進行全球採購，為顧客提供「優質」和「優價」的產品，並為顧客提供舒適的購物環境和愉快的購物體驗。於2025年12月31日，集團合共擁有183間零售店舖，遍佈香港、澳門等人流暢旺的戰略位置，當中包括集團於2021年9月推出全新環球美酒食品店「FoodVille」，主打中高端的環球優質食品。

March 27, 2026

香港國際機場復活節購物賞

多重獎賞: 2X 獎賞積分及Mastercard 簽賬賞高達 HK$1,000 回贈

香港 – Media OutReach Newswire – 2026年3月27日 – HKairport Rewards 呈獻復活節繽紛購物禮遇，包括 2 倍積分、高達 HK$1,000 Mastercard 機場現金券及尊尚腕錶HK$6,000購物賞優惠，為旅客的復活節旅程增添驚喜與歡樂。

復活節購物賞登場立即解鎖機場彩蛋優惠

臨近復活節假期，HKairport Rewards 為會員呈獻多重限定購物禮遇，讓旅客於出發前在機場輕鬆選購各式精品及香港特色手信：

1. 享2X 積分，回贈高達 8%
由 3 月 27 日起至 4 月 12 日期間，旅客於機場店舖或 HKairportShop.com 機場網上商店消費，均可享 2 倍獎賞積分，回贈高達 8%。

每消費港幣 $1 可獲 2 獎賞積分；每 50 積分即可兌換 1 HKIA Dollar，可當作港幣 $1 使用。HKIA Dollar 可於機場超過 100 間參與商戶及餐廳使用，讓旅客盡享購物及餐飲禮遇。

2. Mastercard簽賬獎賞高達港幣$1, 000回贈
於 3 月 20 日至 4 月 12 日推廣期內，旅客於機場店舖或HKairportShop.com機場網上商店以 Mastercard單一消費滿指定金額，即可獲贈 Mastercard 機場電子現金消費券，解鎖多重購物獎賞。

Mastercard 單次消費	Mastercard機場電子現金券
港幣$3,000 – $9,999	港幣$100
港幣$10,000 – $19,999	港幣$400
港幣$20,000 或以上	港幣$1,000

每名會員於推廣期內可兌換各消費級別之Mastercard機場電子現金券一次。

3. 尊尚腕錶$6,000購物優惠
另外，HKairport Rewards 會員由3月12日至 4 月 12 日期間，於機場選購腕錶或相關配件，單一消費滿港幣 50,000 元，即可享立減港幣 6,000 元，相當於12% 折扣，同時可享2X 積分及Mastercard簽賬獎賞!會員只需於「My HKG」流動應用程式內輸入獎賞代碼「WATCH」，即可領取港幣 6,000 元電子現金券。參與推廣的 9 間國際知名品牌包括：Bulgari、Cartier、Chaumet、IWC SCHAFFHAUSEN、Jaeger-LeCoultre、Montblanc、Panerai、Piaget及Tiffany & Co.。

每名會員於推廣期內僅限兌換港幣 6,000 元電子現金券一次。

按此了解更多優惠詳情。

香港國際機場網上商店春季漫遊賞優惠低至5折

春日翩然而至，HKairportShop.com 機場網上商店提供：從清新色彩的行李箱，氣味迷人的春日香水、或在初春出遊期間享用的美酒佳釀，部分產品低至５折優惠，準備好讓您的每段旅程都稱心滿意。由即日起至2026年3月31日，凡於 HKairportShop.com 單一消費淨額滿港幣3,000元，即可獲贈新秀麗旅行卡槽斜揹袋乙個（價值港幣380元），讓隨身物品輕鬆收納！

按此了解更多香港國際機場網上商店最新優惠。

Hashtag: #香港国际机场

The issuer is solely responsible for the content of this announcement.

March 27, 2026

香港国际机场复活节购物赏

多重奖赏: 2X 奖赏积分及Mastercard 签账赏高达 HK$1,000 回赠

香港 – Media OutReach Newswire – 2026年3月27日 – HKairport Rewards 呈献复活节缤纷购物礼遇，包括 2 倍积分、高达 HK$1,000 Mastercard 机场现金券及尊尚腕表HK$6,000购物赏优惠，为旅客的复活节旅程增添惊喜与欢乐。

复活节购物赏登场立即解锁机场彩蛋优惠
临近复活节假期，HKairport Rewards 为会员呈献多重限定购物礼遇，让旅客于出发前在机场轻松选购各式精品及香港特色手信：

1. 享2X 积分，回赠高达 8%
由 3 月 27 日起至 4 月 12 日期间，旅客于机场店铺或 HKairportShop.com 机场网上商店消费，均可享 2 倍奖赏积分，回赠高达 8%。

每消费港币 $1 可获 2 奖赏积分；每 50 积分即可兑换 1 HKIA Dollar，可当作港币 $1 使用。 HKIA Dollar 可于机场超过 100 间参与商户及餐厅使用，让旅客尽享购物及餐饮礼遇。

2. Mastercard签账奖赏高达港币$1, 000回赠
于 3 月 20 日至 4 月 12 日推广期内，旅客于机场店铺或HKairportShop.com机场网上商店以 Mastercard单一消费满指定金额，即可获赠 Mastercard 机场电子现金消费券，解锁多重购物奖赏。

Mastercard 单次消费	Mastercard机场电子现金券
港币$3,000 – $9,999	港币$100
港币$10,000 – $19,999	港币$400
港币$20,000 或以上	港币$1,000

每名会员于推广期内可兑换各消费级别之Mastercard机场电子现金券一次。

3. 尊尚腕表$6,000购物优惠
另外，HKairport Rewards 会员由3月12日至 4 月 12 日期间，于机场选购腕表或相关配件，单一消费满港币 50,000 元，即可享立减港币 6,000 元，相当于12% 折扣，同时可享2X 积分及Mastercard签账奖赏!会员只需于「My HKG」流动应用程式内输入奖赏代码「WATCH」，即可领取港币 6,000 元电子现金券。参与推广的 9 间国际知名品牌包括：Bulgari、Cartier、Chaumet、IWC SCHAFFHAUSEN、Jaeger-LeCoultre、Montblanc、Panerai、Piaget及Tiffany & Co.。

每名会员于推广期内仅限兑换港币 6,000 元电子现金券一次。

按此了解更多优惠详情。

香港国际机场网上商店春季漫游赏优惠低至5折

春日翩然而至，HKairportShop.com 机场网上商店提供：从清新色彩的行李箱，气味迷人的春日香水、或在初春出游期间享用的美酒佳酿，部分产品低至５折优惠，准备好让您的每段旅程都称心满意。由即日起至2026年3月31日，凡于HKairportShop.com 单一消费净额满港币3,000元，即可获赠新秀丽旅行卡槽斜背袋乙个（价值港币380元），让随身物品轻松收纳！

按此了解更多香港国际机场网上商店最新优惠。

Hashtag: #香港国际机场

The issuer is solely responsible for the content of this announcement.

March 27, 2026

Uni-Bio Science Group Limited Announces 2025 Annual Results
Record-Breaking Revenue of HK$586.2M and EPS Surged to HK$1.56 Cents

Dividends Distributed for Two Consecutive Years

Embarks on Innovation-Driven Transformation to Become a Global Pioneer in Regenerative Medicine

HONG KONG SAR – EQS Newswire – 27 March 2026 – A fully integrated biopharmaceutical company – Uni-Bio Science Group Limited (“Uni-Bio Science”, together with its subsidiaries referred to as the “Group”, stock code: 0690.HK), is pleased to announce its annual results for the year ended 31 December 2025 (the “Year”).

Key Accomplishments in 2025
During the Year, the Group achieved a spectrum of accomplishments, for both of its marketed products and innovative biologics. The key highlights include:
1. During the Year, the Group delivered record-breaking financial results, with revenue recorded a 6.0% year-on-year (“YoY”) increase, reaching approximately HK$586.2 million. Profit for the year soared by 12.7% YoY to approximately HK$93.3 million, and net profit margin increased by 1.0 percentage points YoY to 15.9%, marking a historic high. The earnings per share reached approximately HK$1.56 cents, reflecting a growth of 15.5% YoY or a CAGR of 18.55% from 2023 to 2025.
2. The Group generated solid cash from operations in the Year, operating cash flow and free cash flow increased by 32.7% and 27.3% YoY, respectively. Cash ratio increased from 0.53 times at the end of 2024 to 1.63 times at the end of 2025. The cash conversion cycle improved from 124 days to 107 days, highlighting greater operating efficiency. Backed by sustainable earnings and a healthy cash flow, the board of directors (“Board”) has declared a dividend payment for 2025 of HK$0.313 cents per share.
3. Since its official launch in March 2024, Bogutai^® has sustained strong growth momentum, driven by a solid commercialization strategy and successful academic engagement. In 2025, Bogutai^® demonstrated rapid market adoption in China, achieving a remarkable year-on-year revenue growth of 111.0%.
4. In May 2025, the Group’s second ophthalmology product, 金因康^® (Diquafosol Sodium Eye Drops), received marketing approval from the China National Medical Products Administration (“NMPA”), marking a significant milestone in expanding the Group’s ophthalmic portfolio following GeneSoft^®. The Group is actively preparing its launch and marketing strategy. In addition to leveraging synergy with GeneSoft^® and its established online and offline distribution network for rapid market penetration, 金因康^® will specifically target the mid-to-high-end segment of dry eye patients outside the hospital setting, those who prioritize long-term efficacy and premium product quality.
5. In June 2025, the Group officially launched the high-end series GeneQueens^® of 肌顏態^® and the medical device brand 金因敷^®, marking two key milestones in its strategic expansion into the integrated”Drug, Medical Device, and Aesthetics”field. These product launches reflect the Group’s commitment to enhancing its skin health product matrix and addressing evolving consumer needs for efficacy-driven, medical-grade skincare in both functional skincare and post-aesthetic recovery.
6. In July 2025, the marketing application of Isavuconazonium sulfate capsules were officially accepted by the NMPA. Isavuconazonium sulfate capsules are expected to be approved for launch as early as the fourth quarter of 2026, offering a safer, more effective, and high-quality treatment option for patients suffering from invasive fungal infections.
7. In 2025, the Group established a strategic partnership with Wenzhou Medical University to explore a thermosensitive gel formulation combining EGF and bFGF, leveraging the university’s proven expertise in bFGF production. As a key growth factor in regenerative medicine, bFGF is highly effective in promoting granulation and angiogenesis.
8. Towards the end of 2025, the Group repositioned its long-term strategy from “Stable Growth” to “Innovation-Driven,” signifying a bold transformation from an integrated pharmaceutical company into a global pioneer in regenerative medicine. The Group is advancing a transformative R&D strategy spanning four key areas: muscular-skeletal regeneration, skin regeneration, ocular regeneration, and ENT regeneration.
Annual Results
For 2025, the Group recorded a revenue of approximately HK$586.2 million, representing an increase of 6.0% YoY. Revenue from Bogutai^® increased from approximately HK$ $63.5 million to approximately HK$ 134.0 million, representing a significant increase of 111.0%. Revenue generated from GeneTime^® was approximately HK$220.4 million, representing an increase of 10.9% YoY. GeneSoft^® recorded a 7.9% YoY decrease in revenue from approximately HK$41.9 million to approximately HK$38.6 million due to intense market competition. Pinup^® recorded a decrease of 29.4% in revenue from approximately HK$244.2 million to approximately HK$172.5 million for the Year. In 2025, the Group adopted a more disciplined and selective hospital-supply strategy under volume-based procurement (VBP) to safeguard margins, particularly in regions where policy adjustments intensified price competition. At the same time, the Group accelerated diversification into pharmacy networks beyond traditional hospital channels and optimized its supply chain to improve cost and profitability. In 2024, Boshutai^® was successfully included in the VBP by the Henan Seventeen Provinces Alliance and the procurement validity period is set for two years. Hospitals in many provinces began procuring Boshutai^® in 2025. Following the destocking and a low base in 2024, revenue from Boshutai^® increased from approximately HK$10.2 million to approximately HK$15.5 million, representing a significant increase of 51.9%. 肌顏態^® generated approximately HK$2.8 million in revenue in its early stage. The limited revenue scale reflected several factors, including a relatively small number of products approved and launched during the Year, and the fact that specialized marketing and distribution teams were still being built and optimized.

Gross profit was approximately HK$487.6 million, representing an increase of 5.7% as compared with approximately HK$461.1 million in 2024, and gross profit margin increased by 0.2 percentage points YoY to 83.2%. The Group delivered another year of record-breaking profit, achieving approximately HK$93.3 million for the Year, representing an increase of 12.7% YoY. Net profit margin increased by 1.0 percentage points YoY to 15.9%. These results demonstrate the Group’s success in converting product innovation into market value through strong commercialization execution and financial discipline. The earnings per share reached approximately HK$1.56 cents, reflecting a growth of 15.5% YoY.

Prospects
Regenerative medicine has emerged as a rapidly developing field, focused on repairing, replacing, or regenerating damaged tissues or organs using cells, tissues, or genetic material. The sector has the potential to treat and address the underlying causes of chronic and advanced diseases. The global regenerative medicine market was approximately USD51.7 billion in 2025. It is projected to grow from USD63.0 billion in 2026 to USD555.6 billion by 2034, representing a compound annual growth rate (CAGR) of 31.3%. The increasing prevalence of chronic and hereditary diseases, together with rising healthcare expenditure in both developed and emerging markets, is expected to support continued growth in the regenerative medicine industry.

Mr. Kingsley Leung, Chairman of Uni-Bio Science, commented, “In 2025, we are proud to have delivered another year of record profitability, marking a significant milestone in our growth journey. During the year, we entered a new phase of strategic development. In anticipation of an increasingly favorable market environment, we advanced our strategic transition from ‘stable growth’ to ‘innovation-driven’ development, with a clear focus on four diversified therapeutic areas: musculoskeletal regeneration, skin regeneration, ocular regeneration, and ENT regeneration.

With multiple products progressing through our pipeline and accelerating toward commercialization, the Group has continued to broaden its marketing channels. In addition to strengthening our established offline hospital networks, deepening partnerships with local distributors, and hosting academic conferences, we have actively expanded into online e-commerce platforms to enhance product accessibility and extend our market reach. Our ambitions extend well beyond China. During the year, we formed a strategic partnership with Kexing Biopharm to accelerate the global expansion of Bogutai^®. Through this collaboration, we have granted Kexing Biopharm exclusive commercialization rights for Bogutai^® in six international markets—Saudi Arabia, Egypt, Morocco, Colombia, Argentina, and Mexico—laying a solid foundation for global growth. We expect these markets to begin contributing revenue as early as the end of 2026. At the same time, we are advancing the FDA approval process for Bogutai^® in the United States, aiming for approval as early as 2027.

In December, we also entered into a strategic collaboration with Wenzhou Medical University and the People’s Government of Ouhai District, Wenzhou, to foster a synergistic ‘government–university–enterprise’ model, further strengthening our capabilities in regenerative medicine. Supported by strong partnerships with local governments and leading academic institutions, we are well positioned to build a world-class biomedical ecosystem and enhance our end-to-end innovation capabilities.”
Hashtag: #Uni-BioScience

The issuer is solely responsible for the content of this announcement.

About Uni-Bio Science Group Limited

Uni-Bio Science Group Limited is an innovative biopharmaceutical enterprise listed on the Main Board of The Stock Exchange of Hong Kong Limited in 2001 (Stock Code: 00690.HK). The Group is committed to powering the advancement of regenerative medicine with next-generation synthetic biology and complex peptide innovation. Focusing on four core research areas—muscular-skeletal regeneration, skin regeneration, ocular regeneration, and ENT regeneration—the Group has built a diversified product pipeline encompassing innovative biologics, high-value generic drugs, and medical aesthetics. The Group operates GMP-compliant production bases in Beijing, Dongguan, and Shenzhen, with fully integrated capabilities spanning R&D, manufacturing, and commercial sales. Uni-Bio Science Group is dedicated to be the global leader in regenerative medicine, redefining how science restores and extends human life.

For further information, please contact: ir@uni-bioscience.com
March 27, 2026
联康生物科技集团公布2025年全年业绩
收入创新高达586.2百万港元

每股盈利提升至1.56港仙并连续两年派发股息

开启创新驱动转型致力于成为全球再生医学先驱

香港 – EQS Newswire – 2026年3月27日 – 综合性生物制药公司 — 联康生物科技集团有限公司（「联康集团」或「本公司」，连同其附属公司统称「本集团」，股份代号：0690）欣然宣布本集团截至二零二五年十二月三十一止年度(「年内」）的全年业绩。

二零二五年取得之重大成就
年内，本集团取得了一系列成就，在已上市产品及创新的生物制剂方面均取得良好成绩。主要取得的成就如下:
1. 年内，本集团录得破纪录的财务业绩，收入按年增长6. 0%，达到约586. 2百万港元。溢利按年升12.7%至约93.3百万港元，而纯利率按年增加1. 0个百分点至15.9%，创历史新高。每股盈利达到约1. 56港仙，按年增长15.5%，二零二三年至二零二五年的复合年增长率为18.55%。
2. 本集团于年内录得稳健的经营现金流，经营现金流量及自由现金流量分别按年增加32.7%及27.3%。现金比率由二零二四年底的0.53倍上升至二零二五年底的1.63倍。现金转换周期从124天改善为107天，突显营运效率显著提升。凭借可持续盈利及稳健的现金流，董事会建议派发末期股息每股0.313港仙。
3. 自博固泰®于二零二四年三月正式推出以来，在稳健的商业化策略及成功的学术推广驱动下，其保持了强劲的增长势头。于二零二五年，博固泰^®在中国展现出快速的市场渗透率，年收入增长实现111.0%的显著增长。
4. 于二零二五年五月，本集团第二款眼部产品金因康^®（地夸磷索钠滴眼液）获中国国家药品监督管理局(NMPA)的上市批准，标志着继金因舒^®后，本集团眼部产品线拓展之重要里程碑。本集团正积极筹备其推出及营销策略。除利用与金因舒^®及其成熟的在线及线下分销网络的协同效应以实现快速市场渗透外，金因康^®将专门针对医院场景以外的中高端干眼症患者群体，即该等优先考虑长期疗效及优质产品质量的患者。
5. 于二零二五年六月，本集团正式推出肌颜态^®高端系列GeneQueens^®及医疗器械品牌金因敷^®，此举标志其进军「药品、医械及医美」整合领域之两个关键里程碑。该等产品发布反映本集团致力于完善其皮肤健康产品矩阵，并满足消费者对功能性护肤及医美术后修复领域中以功效为导向的医学级护肤品不断演变的需求。
6. 于二零二五年七月，硫酸艾沙康唑胶囊的上市申请已获国家药品监督管理局正式受理。硫酸艾沙康唑胶囊预计最早将于二零二六年第四季度获准上市，为侵入性真菌感染患者提供更安全、更有效且高质量的治疗选择。
7. 于二零二五年，本集团与温州医科大学建立战略合作伙伴关系，利用该大学在bFGF生产方面经证实的专业知识，共同研发结合EGF及bFGF的热敏凝胶制剂。作为再生医学的关键生长因子，bFGF在促进肉芽组织增生及血管生成方面具有高度疗效。
8. 于二零二五年底，本集团将其长期战略由「稳健增长」重新定位为「创新驱动」，标志着其由一家综合制药公司大胆转型为全球再生医学先驱。本集团正推进具变革性的研发战略方向，涵盖四大关键领域：肌肉骨骼再生、皮肤再生、眼部再生及耳鼻喉科再生。
全年业绩

于二零二五年，本集团录得收益约586. 2百万港元，按年增长6. 0%。博固泰^®的收益由约63.5百万港元大幅增加至约134.0百万港元，大幅增加111.0%。金因肽^®的收益约为220.4百万港元，按年增长10.9%。由于市场竞争激烈，金因舒^®的收益由约41.9百万港元按年减少7.9%至约38.6百万港元。匹纳普^®录得的收益由约244.2百万港元减少29.4%至约172.5百万港元。二零二五年，本集团在带量采购下采取了更为严谨且具选择性的医院供应策略，以保障利润率，特别是在政策调整加剧价格竞争的地区。同时，本集团加速向传统医院渠道以外的药房网络多元化发展，并优化其供应链以改善成本及盈利能力。于二零二四年，博舒泰^®成功纳入河南省十七省联盟集中带量采购，采购有效期设定为两年。于二零二五年，许多省份的医院开始采购博舒泰^®。继二零二四年的去库存及较低基数之后，来自博舒泰^®的收益由约10.2百万港元增加至约15.5百万港元，大幅增加51.9%。肌颜态^®在其早期阶段产生约2.8百万港元的收益。有限的收益规模反映了几项因素，包括于年内获批准及推出的产品数量相对较少，以及专业营销及分销团队仍处于组建及优化阶段的事实。

毛利约为487.6百万港元，较二零二四年的约461.1百万港元增加5.7%，而毛利率按年下降0.2个百分点至83.2%。本集团实现约93.3百万港元的破纪录溢利，再次创下新高，按年增长12.7%。净利润率按年上升1.0个百分点至15.9%。该等业绩证明本集团凭借强大的商业化执行力及财务纪律，成功将产品创新转化为市场价值。每股盈利约达1.56港仙，按年增长15.5%。

展望

再生医学已成为一个快速发展的领域，专注于利用细胞、组织或遗传物质修复、更换或再生受损的组织或器官。该行业具有治疗及解决慢性病及晚期疾病潜在病因的潜力。全球再生医学市场于二零二五年约为517亿美元。预计将由二零二六年的630亿美元增长至二零三四年的5,556亿美元，复合年增长率为31.3%。慢性病及遗传性疾病日益普遍，加上发达及新兴市场的医疗保健支出不断增加，预计将支持再生医学行业持续增长。

联康生物科技集团主席梁国龙先生表示：「二零二五年，我们欣然宣布公司又实现了一年的营利突破，标志着集团发展中重要的里程碑。年内，本集团进入策略发展的新阶段。随着市场环境逐步向好，我们积极推进由『稳定增长』转型至『创新驱动』阶段，聚焦肌肉骨骼再生、皮肤再生、眼部再生及耳鼻喉再生四大多元化治疗领域。

随着多项产品正在研发并加速迈向商业化阶段，集团持续拓展多元化营销渠道。在巩固传统医疗网络、加深与本地经销商合作以及开展学术推广活动的同时，我们亦积极布局在线电商平台，以进一步提升产品可及性以及扩大市场覆盖。我们的发展战略不限于中国市场。年内，我们与科兴制药建立了战略合作关系，共同推动博固泰^®的全球化布局。通过此次合作，我们已授权博固泰^®在沙特阿拉伯、埃及、摩洛哥、哥伦比亚、阿根廷及墨西哥六个国际市场的独家商业化权利，为全球业务拓展奠定坚实基础。我们预计上述市场最早将于2026年底开始贡献收益。与此同时，我们正积极推进博固泰^®在美国的FDA注册审批。

二零二五年十二月，我们与温州医科大学及温州市瓯海区人民政府达成战略合作，致力于构建『政产学研』的协同模式，进一步提升公司在再生医学领域的能力。凭借地方政府与顶尖学术机构的有力支持，我们有信心打造一流的生物医药生态体系，以提升全周期能力。」
Hashtag: #Uni-BioScience #联康生物科技

The issuer is solely responsible for the content of this announcement.

关于联康生物科技集团有限公司

联康生物科技集团有限公司是一家于2001年在香港联合交易所主板上市的创新型生物医药企业（股票代码：00690.HK），致力于以下一代合成生物学技术与复杂多肽创新，驱动再生医疗发展。本集团聚焦于骨骼/肌肉再生、皮肤再生、眼部再生及耳鼻喉（ENT）再生四大核心研究领域，构建了涵盖生物创新药、高值仿制药与医疗美容等板块的多元化产品管线。本集团分别于北京、东莞及深圳均设有GMP的生产基地，具备研发、生产及商业化销售的全链条能力。本集团致力于成为再生医学领域的全球领导者，重新定义科学如何修复与延展人类生命。

如欲了解更多信息，请联系： ir@uni-bioscience.com
March 27, 2026
Weiqiao Pioneering Group Adds Sixth National “Green Factory”

BINZHOU, CHINA – Media OutReach Newswire – 27 March 2026 – On March 18, Hongzheng New Materials Technology Co., Ltd. (“Hongzheng New Materials”), based in Zouping, Shandong Province, was designated as a national-level “Green Factory” in the 2025 Green Factory List released by China’s Ministry of Industry and Information Technology. Recognized for its comprehensive green manufacturing system and remarkable achievements in low-carbon transition, Hongzheng New Materials becomes the sixth subsidiary under Weiqiao Pioneering Group to receive this prestigious accreditation.

Hongzheng New Materials Technology Co., Ltd. was designated as a national-level “Green Factory” in the 2025 Green Factory List released by China’s Ministry of Industry and Information Technology.

The national-level “Green Factory” program, led by the Ministry of Industry and Information Technology, is a cornerstone of China’s green manufacturing system. It aims to honor enterprises that lead in efficient land use, non-toxic raw materials, clean production, waste recycling, and low-carbon energy utilization.

Hongzheng New Materials stated that it will further advance the research and application of green and low-carbon technologies to promote the upgrade of aluminum-based materials toward lightweight and high-value-added products, thereby injecting new momentum into the industry’s transition toward greener and more intelligent development.

Hashtag: #BinzhouInformationOffice

The issuer is solely responsible for the content of this announcement.

March 27, 2026
越秀交通業績穩健增長，末期息13港仙

香港 – Media OutReach Newswire – 2026年3月27日 – 受惠於新收購的河南平臨高速的新貢獻和財務表現改善，越秀交通(1052) 2025年收入按年上升12.0%至43.3億元（人民幣，同下），股東應佔盈利為5.3億元。若扣除一次性減值損失影響後的股東應佔盈利為7.1億元，增長8.4%。

公司派發末期息每股13港仙，連同中期息12港仙，全年股息為每股25港仙，按年持平。

公司財務結構持續優化，資產質量持續提升。上年度資產負債率降至57.7%，整體加權平均利率降至2.51%，財務費用按年減少約5,600萬元。

董事長劉艷表示，面向「十五五」規劃期，公司將堅定踐行「做大做新」的發展策略，鞏固高速公路優質資產基本盤，穩步推進改擴建項目，持續提升資產質量與運營效益。同時，將依托母公司優勢，積極佈局路衍經濟與新興基建，推動平台發展，打造高質量發展新格局。

公司2025年資本性開支為10.5億元；2026年預計資本性開支約17.9億元，主要包括工程提升和北二環改擴建。Hashtag: #越秀交通

The issuer is solely responsible for the content of this announcement.

March 27, 2026
Second National Showcase of Outstanding Works from China’s Rare Operatic Genres Held

BINZHOU, CHINA – Media OutReach Newswire – 27 March 2026 – Recently, the second National Showcase of Outstanding Works from China’s Rare Operatic Genres , titled “Ancient Echoes, Treasured Legacies,” was held in Boxing County, Binzhou City, Shandong Province. The event was co-organized by the China Theatre Association, the Shandong Federation of Literary and Art Circles, and other cultural organizations.

The second National Showcase of Outstanding Works from China’s Rare Operatic Genres was held in Boxing County, Binzhou City

Rare operatic genres, often referred to as endangered theatrical forms, are typically characterized by strong regional identities, limited reach, scarce inheritors, and relatively small scale. Shaped over centuries, they embody distinctive musical styles and performance forms of high artistic value and deep cultural resonance. As an integral part of intangible cultural heritage, they preserve local dialects, customs, and cultural ideals..Their protection, transmission, and revitalization are essential to strengthening the foundations of Chinese opera and advancing the creative transformation and innovative development of traditional Chinese culture.

This year’s showcase drew participation from over 100 troupes nationwide, with 36 outstanding works selected. Covering genres such as Yong Opera, Qian Opera, Qi Opera, Dunqiang, and Yong Opera, the showcase highlighted recent progress in safeguarding and revitalizing China’s rare operatic traditions.

Hashtag: #BinzhouInformationOffice

The issuer is solely responsible for the content of this announcement.

March 27, 2026
Singapore-Led Alliance Launches Professional Services Centre in Nanjing to Support Chinese Enterprises’ Expansion across Southeast Asia

SINGAPORE – Media OutReach Newswire – 27 March 2026 – The Institute of Singapore Chartered Accountants (ISCA), together with its Professional Services (PS) Centre Alliance partners, comprising Association of Small & Medium Enterprises, Institute of Valuers & Appraisers, Singapore Business Federation (SBF), Singapore Chinese Chamber of Commerce & Industry (SCCCI), Singapore Manufacturing Federation, Tax Academy of Singapore and the Law Society of Singapore, has launched the PS Centre in Nanjing. This marks the Alliance’s second PS Centre in China and its third globally, strengthening a growing network to support enterprises expanding across China, Singapore and Southeast Asia.

Amid rising demand from businesses seeking overseas growth, the PS Centre was established as a trusted platform to connect enterprises with trusted professional services expertise and in-market networks, enabling smoother and more effective cross-border expansion. Nanjing is strategically positioned, with strong linkages to universities that support talent pipelines, as well as ecosystem builders such as the Singapore-Nanjing Eco Hi-tech Island that help businesses establish and maintain operational presence in the market.

Since its inception, the PS Centres in China and Vietnam have provided on-the-ground support and facilitated opportunities for over 100 businesses. Prior to the launch in Nanjing, the PS Centre has already supported several Small and Medium-sized Enterprises (SMEs) in establishing operations and building local teams. One such example is BIPO, a HR solutions provider, which successfully set up its presence in Nanjing with support from the PS Centre ecosystem.

Mr Michael Chen, CEO of BIPO (Asia) shared: “The launch of the Professional Services Centre marks an important step in enabling more efficient and scalable global expansion for enterprises. As companies expand across markets, what they increasingly need is not just individual services, but an integrated ecosystem of professional capabilities. At BIPO, we are proud to partner with ISCA and the broader professional community to provide the HR technology and operational infrastructure that supports this ecosystem, helping businesses build sustainable, compliant, and tech-enabled global operations.”

The launch took place at the forum titled “Bridging Singapore and Nanjing, Charting Opportunities from ASEAN to China“, organised by the PS Alliance and co-hosted by China-Singapore Nanjing Eco-Tech Island Investment Development Co., Ltd. The forum brought together government representatives, professional bodies, financial institutions and business leaders from both Singapore and China.

Mr Xu Feng, Vice Mayor of Nanjing, highlighted the growing economic linkages between China and Southeast Asia: “Nanjing and Singapore share a long-standing friendship built upon a strong foundation of cooperation. We recognise that the international expansion of enterprises relies on the support of professional services. As a global hub for professional services, Singapore offers complementary strengths, and the prospects for collaboration between our two sides are vast. Nanjing will continue to foster a world-class international business environment, enhance its end-to-end support systems for enterprises expanding overseas, and promote mutually beneficial partnerships between enterprises and Singapore’s professional institutions.”

Mr Ernie Koh, Council Member, SBF / Vice-Chairman, Research & Publications Committee, SCCCI said: “Singapore and China share strong and enduring economic ties, and platforms like the Nanjing PS Centre play a critical role in deepening these linkages. By bringing together business networks and professional expertise, the Alliance can better support enterprises in navigating new markets, strengthening their capabilities, and unlocking opportunities across Southeast Asia. This collaboration reflects our shared commitment to enabling sustainable, cross-border growth.”

Mr Daniel Koh, Vice-President, The Law Society of Singapore, said: “As businesses expand across borders, navigating legal and regulatory complexities becomes increasingly critical. The establishment of the PS Centre provides a valuable platform for enterprises to access trusted legal expertise alongside other professional services. By strengthening cross-border collaboration, we can help businesses operate with greater confidence, manage risks effectively, and build resilient foundations for international growth.”

Mr Darren Ku, Council Member, ASME, said: “For many SMEs, internationalisation presents both significant opportunities and challenges. The Nanjing PS Centre offers a practical and structured gateway for businesses to access the professional support they need, from compliance to market entry strategies. By lowering barriers and providing coordinated expertise, the Alliance will empower more SMEs to expand into Southeast Asia with greater confidence and clarity.”

Beyond facilitating business expansion, the Nanjing PS Centre will also anchor talent development and cross-border capabilities. ISCA has established partnerships with key institutions including Nanjing University of Finance and Economics, Nanjing Audit University, and Jiangsu Certified Public Accountants, laying the foundation for a sustainable pipeline of internationally-ready accounting professionals.

ISCA President Mr Teo Ser Luck said: “The Professional Services Centre in Nanjing shows our commitment to helping Chinese and Singapore businesses grow with good governance, proper compliance, and sound financial management as they expand across the region. Through working together, we can help businesses grow with confidence and in a sustainable way. We plan to bring this model to other parts of the world, so we can continue sharing knowledge and networks with businesses operating across borders.”

With regions such as Shenzhen, Johor Bahru, and Bangkok earmarked for new PS Centres, the PS Alliance has highlighted their commitment to supporting businesses in their cross-border endeavours and operations. By providing a platform for them to explore new opportunities for growth and talent development, these PS Centres play a vital role in cross-border professional development.

The launch of Nanjing PS Centre will serve as a platform to integrate professional resources from Singapore and Jiangsu, supporting enterprises investing in Singapore and across ASEAN. This initiative, coupled with future expansion into other regions, further underscores ISCA’s continued role in strengthening cross-border collaboration and enabling resilient, future-ready business growth.

Hashtag: #ISCA #DifferenceMakers #Accounting #Accountancy #CharteredAccountants #ChooseAccountancy #Singapore #China #Nanjing #PSCentre #Alliance

The issuer is solely responsible for the content of this announcement.

Institute of Singapore Chartered Accountants (ISCA)

The Institute of Singapore Chartered Accountants (ISCA) is the national accountancy body of Singapore. Established in 1963, ISCA administers the Singapore Chartered Accountant Qualification programme and is the designated entity by the Singapore Ministry of Finance to confer the Chartered Accountant of Singapore [CA (Singapore)] designation.

ISCA supports over 43,000 members across industries in Singapore and globally, with members in more than 40 countries. With a growing international presence, ISCA has 12 overseas chapters, 7 offices across 10 countries and a network of over 150 strategic partners, strengthening professional connections and opportunities across borders. ISCA is also a member of Chartered Accountants Worldwide, a global network representing more than 1.8 million Chartered Accountants and students across over 190 countries.

ISCA advances professional development and lifelong learning through ISCA Academy, its training arm and drives community impact through ISCA Cares, its charity arm.

For more information, visit www.isca.org.sg.

March 27, 2026